Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods

References

• Abdallah IA, El-Behairy MF, Ahmed RM, Fayed MAA. 2022. The anti-COVID-19 drug Favipiravir: degradation, Method development, Validation, NMR/LC–MS characterization, and In-vitro safety evaluation. Chem Zvesti. 76(10):6415–6426. doi:10.1007/s11696-022-02327-5.
   PubMed Web of Science ®Google Scholar
• Abo-Gharam AH, El-Kafrawy DS. 2022. Eco-friendly stability-indicating HPTLC micro-determination of the first FDA approved SARS-CoV-2 antiviral prodrug Remdesivir: study of degradation kinetics and structural elucidation of the degradants using HPTLC-MS. Sustain Chem Pharm. 29:100744. doi:10.1016/j.scp.2022.100744.
   PubMed Web of Science ®Google Scholar
• Agrawal U, Raju R, Udwadia ZF. 2020. Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India. 76(4):370–376. doi:10.1016/j.mjafi.2020.08.004.
   PubMedGoogle Scholar
• Ahmed SA, Abdelrheem DA, El-Mageed HRA, Mohamed HS, Rahman AA, Elsayed KNM, Ahmed SA. 2020. Destabilizing the structural integrity of COVID-19 by caulerpin and its derivatives along with some antiviral drugs: an in silico approaches for a combination therapy. Struct Chem. 31(6):2391–2412. doi:10.1007/s11224-020-01586-w.
   PubMed Web of Science ®Google Scholar
• Ali AS, Ibrahim IM, Burzangi AS, Ghoneim RH, Aljohani HS, Alsamhan HA, Barakat J. 2021. Scoping insight on antiviral drugs against COVID-19. Arab J Chem. 14(10):103385. doi:10.1016/j.arabjc.2021.103385.
   PubMed Web of Science ®Google Scholar
• Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, Tsuda Y. 2007. The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv Drug Deliv Rev. 59(1):29–37. doi:10.1016/j.addr.2006.10.006.
   PubMed Web of Science ®Google Scholar
• Al-Shuaeeb RAA, Abd El-Mageed HR, Ahmed SA, Mohamed HS, Hamza ZS, Rafi MO, Rahman MS. 2023. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg12O12 and Zn12O12 nanoclusters: an in silico strategy for COVID-19 treatment. J Biomol Struct Dyn. 41(21):11437–11449. doi:10.1080/07391102.2022.2162967.
   PubMed Web of Science ®Google Scholar
• Alvarez J-C, Moine P, Etting I, Annane D, Larabi IA. 2020. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. Clin Chem Lab Med. 58(9):1461–1468.), doi:10.1515/cclm-2020-0612.
   PubMed Web of Science ®Google Scholar
• Aydoğmuş Z, Asfoor A. 2022. Electroanalytical methods for determination of antiviral drugs in pharmaceutical formulation and biological fluids: a review. Chin J Anal Chem. 50(10):100063. doi:10.1016/j.cjac.2022.100063.
   Web of Science ®Google Scholar
• Azeemuddin M, Sharma HK. 2022. Method development and validation for the simultaneous estimation of remdesivir in bulk and pharmaceutical dosage form and stability studies by UPLC. J Pharmaceut Negat Results. 13(7): 7682–7689. doi:10.47750/pnr.2022.13.S07.928.
   Google Scholar
• Baertschi SW, Alsante KM, Reed RA. 2016. Pharmaceutical stress testing: predicting drug degradation. Boca Raton, USA: CRC Press.
   Google Scholar
• Bajaj S, Singla D, Sakhuja N. 2012. Stability testing of pharmaceutical products. J Appl Pharmaceut Sci. 2(3):129–138.
   Google Scholar
• Brittain, H.G., 2002. Profiles of drug substances, excipients, and related methodology. Anal Profiles Drug Subst Excipents 29, 1–5.
   Google Scholar
• Bakshi M, Singh S. 2002. Development of validated stability-indicating assay methods–critical review. J Pharm Biomed Anal. 28(6):1011–1040. doi:10.1016/s0731-7085(02)00047-x.
   PubMed Web of Science ®Google Scholar
• Balu PA, Paresh MS. 2021. Stability‐indicating RP HPLC method development for estimation of favipiravir in bulk and pharmaceutical dosage form. World J Pharm Res. 10(14):1444–1465.
   Google Scholar
• Baranovich T, Wong S-S, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA. 2013. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol. 87(7):3741–3751. doi:10.1128/JVI.02346-12.
   PubMed Web of Science ®Google Scholar
• Bendas ER, Rezk MR, Badr KA. 2023. Does the ethnic difference affect the pharmacokinetics of favipiravir? A pharmacokinetic study in healthy egyptian volunteers and development of level c in-vitro in-vivo correlation. Drug Res. 73(6):349–354.
   Google Scholar
• Bharskar G, Malvade P. 2022. Favipiravir: an antiviral drug. RJPDFT. 14(4):253–260. doi:10.52711/2349-2988.2022.00041.
   Google Scholar
• Bhaskar R, Ola M, Agnihotri V, Chavan A, Girase H. 2020. Current trend in performance of forced degradation studies for drug substance and drug Product’s. J Drug Delivery Ther. 10(2-s):149–155. doi:10.22270/jddt.v10i2-s.4040.
   Google Scholar
• Biswas P, Hasan MM, Dey D, Dos Santos Costa AC, Polash SA, Bibi S, Ferdous N, Kaium MA, Rahman MDH, Jeet FK, et al. 2021. Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. Environ Sci Pollut Res Int. 28(42):59570–59593. doi:10.1007/s11356-021-16096-3.
   PubMed Web of Science ®Google Scholar
• Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Garza NL, Donnelly G, Cazares LH, Soloveva V, Welch L, et al. 2018. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus. Antiviral Res. 151:50–54. doi:10.1016/j.antiviral.2017.12.020.
   PubMed Web of Science ®Google Scholar
• Blessy M, Patel RD, Prajapati PN, Agrawal YK. 2014. Development of forced degradation and stability indicating studies of drugs—A review. J Pharm Anal. 4(3):159–165. doi:10.1016/j.jpha.2013.09.003.
   PubMedGoogle Scholar
• Bolcato G, Bissaro M, Pavan M, Sturlese M, Moro S. 2020. Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir. Sci Rep. 10(1):20927. doi:10.1038/s41598-020-77700-z.
   PubMed Web of Science ®Google Scholar
• Bulduk I, Akbel E. 2021. A comparative study of HPLC and UV spectrophotometric methods for remdesivir quantification in pharmaceutical formulations. J Taibah Univ Sci. 15(1):507–513. doi:10.1080/16583655.2021.1991737.
   Web of Science ®Google Scholar
• Bulduk İ. 2021. Comparison of HPLC and UV spectrophotometric methods for quantification of favipiravir in pharmaceutical formulations. Iran J Pharmaceutical Res IJPR. 20(3):57.
   Google Scholar
• Bulduk İ. 2021. HPLC-UV method for quantification of favipiravir in pharmaceutical formulations. Acta Chromatographica. 33(3):209–215. doi:10.1556/1326.2020.00828.
   Web of Science ®Google Scholar
• Chandramore K, Sonawane S. 2022. Overview on development and validation of force degradation studies with stability indicating methods. Biosci, Biotech Res Asia. 19(4):881–894. doi:10.13005/bbra/3039.
   Google Scholar
• Chitturi SR, Bharathi C, Reddy AVR, Reddy KC, Sharma HK, Handa VK, Dandala R, Bindu VH. 2008. Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance. J Pharm Biomed Anal. 48(5):1430–1440. doi:10.1016/j.jpba.2008.09.015.
   PubMed Web of Science ®Google Scholar
• Choy K-T, Wong AY-L, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP-H, Huang X, et al. 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178:104786. doi:10.1016/j.antiviral.2020.104786.
   PubMed Web of Science ®Google Scholar
• Christine JK, Hammer SM. n.d. Chapter 145 - Antiretroviral agents. In: Infectious diseases. 3rd ed., Vol. 2, p. 1434–1453. Mosby, USA: Elsevier.
   Google Scholar
• Corbett AH, Lim ML, Kashuba AD. 2002. Kaletra (lopinavir/ritonavir). Ann Pharmacother. 36(7-8):1193–1203. doi:10.1345/aph.1A363.
   PubMed Web of Science ®Google Scholar
• Da Ruos J, Baldo MA, Daniele S. 2023. Analytical methods for the determination of major drugs used for the treatment of COVID-19. A review. Crit Rev Anal Chem. 53(8):1698–1732. doi:10.1080/10408347.2022.2039094.
   PubMed Web of Science ®Google Scholar
• Dadinaboyina SB, Yerra NV, Adimoolam BM, Parsa S, Bathini NB, Thota JR. 2021. Identification and characterization of degradation products of Remdesivir using liquid chromatography/mass spectrometry. New J Chem. 45(16):7217–7224. doi:10.1039/D1NJ00160D.
   Web of Science ®Google Scholar
• Deb S, Reeves AA, Hopefl R, Bejusca R. 2021. ADME and pharmacokinetic properties of remdesivir: its drug interaction potential. Pharmaceuticals. 14(7):655. doi:10.3390/ph14070655.
   Web of Science ®Google Scholar
• Delang L, Abdelnabi R, Neyts J. 2018. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 153:85–94. doi:10.1016/j.antiviral.2018.03.003.
   PubMed Web of Science ®Google Scholar
• Donato EM, Dias CL, Rossi RC, Valente RS, Fröehlich PE, Bergold AM. 2006. LC method for studies on the stability of lopinavir and ritonavir in soft gelatin capsules. Chroma. 63(9-10):437–443. doi:10.1365/s10337-006-0785-y.
   Web of Science ®Google Scholar
• Du YX, Chen XP. 2020. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clin Pharmacol Ther. 108(2):242–247. doi:10.1002/cpt.1844.
   PubMed Web of Science ®Google Scholar
• Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. 2020. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 6(5):672–683. doi:10.1021/acscentsci.0c00489.
   PubMed Web of Science ®Google Scholar
• Eckhardt BJ, Gulick RM. 2017. 152 - Drugs for HIV Infection. In: Infectious Diseases, 4th ed. Vol. 2, p. 1293–1308.e2. Mosby, USA: Elsevier.
   Google Scholar
• Ehrhardt M, Möck M, Haefeli WE, Mikus G, Burhenne J. 2007. Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. J Chromatogr B Analyt Technol Biomed Life Sci. 850(1-2):249–258. doi:10.1016/j.jchromb.2006.11.037.
   PubMed Web of Science ®Google Scholar
• El-Mageed HRA, Abdelrheem DA, Ahmed SA, Rahman AA, Elsayed KNM, Ahmed SA, El-Bassuony AA, Mohamed HS. 2021. Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study. Struct Chem. 32(4):1415–1430. doi:10.1007/s11224-020-01723-5.
   PubMed Web of Science ®Google Scholar
• Elmansi H, Ibrahim AE, Mikhail IE, Belal F. 2021. Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma. Anal Methods. 13(23):2596–2602. doi:10.1039/d1ay00469g.
   PubMed Web of Science ®Google Scholar
• Eroglu E, Toprak C. 2021. Overview of favipiravir and remdesivir treatment for COVID-19. Int J Pharm Sci Res. 12(4):1950–1957.
   Google Scholar
• Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 100(2):446–454. doi:10.1016/j.antiviral.2013.09.015.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Komeno T, Nakamura T. 2017. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 93(7):449–463. doi:10.2183/pjab.93.027.
   PubMed Web of Science ®Google Scholar
• Golden MH, Cooper DC, Riebe MT, Carswell KE. 1996. A matrixed approach to long-term stability testing of pharmaceutical products. J Pharm Sci. 85(2):240–245. doi:10.1021/js950034i.
   PubMed Web of Science ®Google Scholar
• González-González O, Ramirez IO, Ramirez BI, O’Connell P, Ballesteros MP, Torrado JJ, Serrano DR. 2022. Drug Stability: ICH versus Accelerated Predictive Stability Studies. Pharmaceutics. 14(11):2324. doi:10.3390/pharmaceutics14112324.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 295(20):6785–6797. doi:10.1074/jbc.RA120.013679.
   PubMed Web of Science ®Google Scholar
• Gouda AS, Abdel-Megied AM, Rezk MR, Marzouk HM. 2023. LC-MS/MS-based metabolite quantitation of the antiviral prodrug baloxavir marboxil, a new therapy for acute uncomplicated influenza, in human plasma: application to a human pharmacokinetic study. J Pharm Biomed Anal. 223:115165. doi:10.1016/j.jpba.2022.115165.
   PubMed Web of Science ®Google Scholar
• Gouda AS, Marzouk HM, Rezk MR, Abdel-Megied AM. 2023. Ecofriendly stability-indicating UHPLC-PDA method for determination of the new influenza antiviral prodrug Baloxavir Marboxil; application to degradation kinetic studies and structure elucidation of the major degradation products using LC-MS. Sustainable Chem Pharm. 33:101093. doi:10.1016/j.scp.2023.101093.
   Web of Science ®Google Scholar
• Gouda AS, Marzouk HM, Rezk MR, Salem AM, Morsi MI, Nouman EG, Abdallah YM, Hassan AY, Abdel-Megied AM. 2022. A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 1206:123363. doi:10.1016/j.jchromb.2022.123363.
   PubMed Web of Science ®Google Scholar
• Gudima G, Kofiadi I, Shilovskiy I, Kudlay D, Khaitov M. 2023. Antiviral Therapy of COVID-19. IJMS. 24(10):8867. doi:10.3390/ijms24108867.
   Google Scholar
• Guideline I. 2003. Stability testing of new drug substances and products. Q1A (R2), Current Step. 4:1–24. (
   Google Scholar
• Gülhan R, Eryüksel E, Gülçebi İdriz Oğlu M, Çulpan Y, Toplu A, Kocakaya D, Tigen E, Ertürk Şengel B, Sili U, Olgun Yıldızeli Ş, et al. 2022. Pharmacokinetic characterization of favipiravir in patients with COVID‐19. Br J Clin Pharmacol. 88(7):3516–3522. doi:10.1111/bcp.15227.
   PubMed Web of Science ®Google Scholar
• Hamdy MM, Abdel Moneim MM, Kamal MF. 2021. Accelerated stability study of the ester prodrug remdesivir: recently FDA‐approved Covid‐19 antiviral using reversed‐phase‐HPLC with fluorimetric and diode array detection. Biomed Chromatogr. 35(12):e5212. doi:10.1002/bmc.5212.
   PubMed Web of Science ®Google Scholar
• Huang Y, Huang X, Luo Y, Zhou Y, Tao X, Chen H, Song A, Chen Y, Wu H. 2018. Assessing the efficacy of lopinavir/ritonavir-based preferred and alternative second-line regimens in HIV-infected patients: a meta-analysis of key evidence to support WHO recommendations. Front Pharmacol. 9:890. doi:10.3389/fphar.2018.00890.
   PubMed Web of Science ®Google Scholar
• Jain D, Basniwal PK. 2013. Forced degradation and impurity profiling: recent trends in analytical perspectives. J Pharm Biomed Anal. 86:11–35. doi:10.1016/j.jpba.2013.07.013.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, et al. 2020. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 582(7811):289–293. doi:10.1038/s41586-020-2223-y.
   PubMed Web of Science ®Google Scholar
• Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One. 8(7):e68347. doi:10.1371/journal.pone.0068347.
   PubMed Web of Science ®Google Scholar
• Jorgensen SC, Kebriaei R, Dresser LD. 2020. Remdesivir: review of pharmacology, pre‐clinical data, and emerging clinical experience for COVID‐19. Pharmacother J Hum Pharmacol Drug Ther. 40(7):659–671. doi:10.1002/phar.2429.
   Google Scholar
• Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. 2021. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 102:501–508. doi:10.1016/j.ijid.2020.10.069.
   PubMed Web of Science ®Google Scholar
• Kalvatchev N, Sirakov I. 2021. Respiratory viruses crossing the species barrier and emergence of new human coronavirus infectious disease. Biotechnology & Biotechnological Equipment. 35(1):37–42. doi:10.1080/13102818.2020.1843539.
   Web of Science ®Google Scholar
• Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, Akram M, Riaz M, Rasool G, Hamid Khan A, Saleem I, Shamim S, Malik A, et al. 2021. A review: mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol. 35:20587384211002621. doi:10.1177/20587384211002621.
   Web of Science ®Google Scholar
• Khalil HA, Hassanein NA, El-Yazbi AF. 2023. Recent analytical methodologies for the determination of anti-covid-19 drug therapies in various matrices: a critical review. RSC Adv. 13(19):13224–13239. doi:10.1039/d3ra00654a.
   PubMed Web of Science ®Google Scholar
• Killi GD, Maddinapudi RK, Dinakaran SK, Harani A. 2014. A novel validated UPLC method for quantitation of lopinavir and ritonavir in bulk drug and pharmaceutical formulation with its impurities. Braz J Pharm Sci. 50(2):301–308. doi:10.1590/S1984-82502014000200009.
   Web of Science ®Google Scholar
• Kommanaboyina B, Rhodes CT. 1999. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm. 25(7):857–868. doi:10.1081/ddc-100102246.
   PubMed Web of Science ®Google Scholar
• Konstantinova ID, L Andronova V, Fateev IV, Esipov RS. 2022. Favipiravir and Its Structural Analogs: antiviral Activity and Synthesis Methods. Acta Naturae. 14(2):16–38. doi:10.32607/actanaturae.11652.
   PubMed Web of Science ®Google Scholar
• Kumar GN, et al. 1999. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos. 27(1):86–91.
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Ma X. 2012. CPY3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. Drug Metab Dispos. 40(1):18–24. doi:10.1124/dmd.111.041400.
   PubMed Web of Science ®Google Scholar
• Li J-Y, You Z, Wang Q, Zhou Z-J, Qiu Y, Luo R, Ge X-Y. 2020. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 22(2):80–85. doi:10.1016/j.micinf.2020.02.002.
   PubMed Web of Science ®Google Scholar
• Lynch T, Neff AP. 2007. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician. 76(3):391–396.
   PubMed Web of Science ®Google Scholar
• Madelain V, Nguyen THT, Olivo A, de Lamballerie X, Guedj J, Taburet A-M, Mentré F. 2016. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 55(8):907–923. doi:10.1007/s40262-015-0364-1.
   PubMed Web of Science ®Google Scholar
• Martinez MA. 2022. Efficacy of repurposed antiviral drugs: lessons from COVID-19. Drug Discov Today. 27(7):1954–1960. doi:10.1016/j.drudis.2022.02.012.
   PubMed Web of Science ®Google Scholar
• Marzouk HM, Gouda AS, Rezk MR, Abdel-Megied AM. 2024. A validated LC-MS/MS method for determination of Molnupiravir and Favipiravir in human plasma; Assessment of the remarkable potential synergistic effect against SARS-CoV-2 Infection: application to a pharmacokinetic study in healthy Egyptian volunteers. Microchem J. 197:109815. doi:10.1016/j.microc.2023.109815.
   Web of Science ®Google Scholar
• Marzouk HM, Rezk MR, Gouda AS, Abdel-Megied AM. 2022. A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling. Microchem J. 172:106917. doi:10.1016/j.microc.2021.106917.
   Web of Science ®Google Scholar
• Megahed SM, Habib AA, Hammad SF, Kamal AH. 2021. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: application to spiked human plasma. Spectrochim Acta A Mol Biomol Spectrosc. 249:119241. doi:10.1016/j.saa.2020.119241.
   PubMed Web of Science ®Google Scholar
• Mei M, Tan X. 2021. Current strategies of antiviral drug discovery for COVID-19. Front Mol Biosci. 8:671263. doi:10.3389/fmolb.2021.671263.
   PubMed Web of Science ®Google Scholar
• Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C. 2020. Role of Lopinavir/Ritonavir in the treatment of Covid-19: a review of current evidence, guideline recommendations, and perspectives. J Clin Med. 9(7):2050. doi:10.3390/jcm9072050.
   PubMed Web of Science ®Google Scholar
• Mikhail IE, Elmansi H, Belal F, Ehab Ibrahim A. 2021. Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens. Microchem J. 165:106189. doi:10.1016/j.microc.2021.106189.
   Web of Science ®Google Scholar
• Nagulwar V, Bhusari K. 2012. Development of UV spectrophotometric first order derivative method for the simultaneous estimation of ritonavir and lopinavir in combined tablet dosage form. Int J Pharm Sci Res. 3(7):2317.
   Google Scholar
• Naydenova K, Muir KW, Wu L-F, Zhang Z, Coscia F, Peet MJ, Castro-Hartmann P, Qian P, Sader K, Dent K, et al. 2021. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. p. Proc Natl Acad Sci USA. 118(7):e2021946118. doi:10.1073/pnas.2021946118.
   PubMed Web of Science ®Google Scholar
• Negru PA, Radu A-F, Vesa CM, Behl T, Abdel-Daim MM, Nechifor AC, Endres L, Stoicescu M, Pasca B, Tit DM, et al. 2022. Therapeutic dilemmas in addressing SARS-CoV-2 infection: favipiravir versus Remdesivir. Biomed Pharmacother. 147:112700. doi:10.1016/j.biopha.2022.112700.
   PubMed Web of Science ®Google Scholar
• Niu W-J, Sun T, Liu L, Liu X-Q, Zhang R-F, Yin L, Wang J-R, Jia X-F, Lu H-Z, Zhong M-K, et al. 2019. Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV. Basic Clin Pharmacol Toxicol. 124(4):456–465. doi:10.1111/bcpt.13154.
   PubMed Web of Science ®Google Scholar
• Noureldeen DAM, Boushra JM, Lashien AS, Hakiem AFA, Attia TZ. 2022. Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs “Remdesivir and Favipiravir”: Green assessment with application to pharmaceutical formulations and human plasma. Microchem J. 174:107101. doi:10.1016/j.microc.2021.107101.
   Web of Science ®Google Scholar
• Nutho B, Mahalapbutr P, Hengphasatporn K, Pattaranggoon NC, Simanon N, Shigeta Y, Hannongbua S, Rungrotmongkol T. 2020. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry. 59(18):1769–1779. doi:10.1021/acs.biochem.0c00160.
   PubMed Web of Science ®Google Scholar
• Padhye H, Sonawane B, Munipalli VK, Paranjpe AS, Singh RM, Nayak S, Bhaskar V, 2022. Stability indicating RP-HPLC method for determination of remdesivir in sublingual tablet dosage form. Inter Res J Pharm Med Sci. 5(3):17–23.
   Google Scholar
• Pasupuleti RR, Tsai P-C, Ponnusamy VK, Pugazhendhi A. 2021. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients. Process Biochem. 102:150–156. doi:10.1016/j.procbio.2020.12.014.
   PubMed Web of Science ®Google Scholar
• Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. 2021. Efficacy and safety of lopinavir-ritonavir in COVID-19: a systematic review of randomized controlled trials. J Infect Public Health. 14(6):740–748. doi:10.1016/j.jiph.2021.03.015.
   PubMed Web of Science ®Google Scholar
• Qomara WF, Primanissa DN, Amalia SH, Purwadi FV, Zakiyah N. 2021. Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review. Int J Gen Med. 14:8557–8571. doi:10.2147/IJGM.S332458.
   PubMed Web of Science ®Google Scholar
• Reethu Sree C, Babu B, Keerthivasan B, Vinay B, Balaji R, Gowtham GP, Ramesh J. 2023. Stability indicating analytical method of favipiravir API-identification and characterization of its degradant by forced degradation studies using LC-MS. J Electric Mach Control. 16(3):1–9.
   Google Scholar
• Rezk MR, Badr KA, Abdel-Naby NS, Ayyad MM. 2021. A novel, rapid and simple UPLC–MS/MS method for quantification of favipiravir in human plasma: application to a bioequivalence study. Biomed Chromatogr. 35(7):e5098. doi:10.1002/bmc.5098.
   PubMed Web of Science ®Google Scholar
• Sahin G, Akbal-Dagistan O, Culha M, Erturk A, Basarir NS, Sancar S, Yildiz-Pekoz A. 2022. Antivirals and the potential benefits of orally inhaled drug administration in COVID-19 treatment. J Pharm Sci. 111(10):2652–2661. doi:10.1016/j.xphs.2022.06.004.
   PubMed Web of Science ®Google Scholar
• Salem A, Gouda A, Marzouk H, Rezk M, Abdel-Megied A. 2023. A population pharmacokinetic modeling approach to evaluate the current dosing recommendations of favipiravir in Egyptian subjects. Inter J Infect Dis. 130:s 94. doi:10.1016/j.ijid.2023.04.234.
   Web of Science ®Google Scholar
• Sánchez-Hernández A, García-Gómez D, Pérez Pavón JL, Rodríguez-Gonzalo E. 2024. Simultaneous determination of favipiravir and surrogates of its metabolites by means of heart-cutting bidimensional liquid chromatography (2D-LC). Anal Biochem. 684:115375. doi:10.1016/j.ab.2023.115375.
   PubMed Web of Science ®Google Scholar
• Seshachalam U, Haribabu B, Chandrasekhar K. 2007. A novel validated LC method for quantitation of lopinavir in bulk drug and pharmaceutical formulation in the presence of its potential impurities and degradation products. Biomed Chromatogr. 21(7):716–723. doi:10.1002/bmc.810.
   PubMed Web of Science ®Google Scholar
• Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G, Fattorini V, Ferron F, Decroly E, Meier C, et al. 2020. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv. doi:10.1101/2020.05.15.098731.
   Google Scholar
• Shannon A, Selisko B, Le N-T-T, Huchting J, Touret F, Piorkowski G, Fattorini V, Ferron F, Decroly E, Meier C, et al. 2020. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 11(1):4682. doi:10.1038/s41467-020-18463-z.
   PubMed Web of Science ®Google Scholar
• Sharaf YA, El Deeb S, Ibrahim AE, Al-Harrasi A, Sayed RA. 2022. Two green micellar HPLC and mathematically assisted UV spectroscopic methods for the simultaneous determination of molnupiravir and favipiravir as a novel combined COVID-19 antiviral regimen. Molecules. 27(7):2330. doi:10.3390/molecules27072330.
   PubMed Web of Science ®Google Scholar
• Shivanand NHB, Charushila H. 2015. Development and validation of a stability indicating HPLC method for the simultaneous analysis of lopinavir and ritonavir in fixed-dose combination tablets. J Taibah Univ Med Sci. 10(3):271–277.
   Google Scholar
• Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. 2020. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 17(1):141. doi:10.1186/s12985-020-01412-z.
   PubMed Web of Science ®Google Scholar
• Singhal T. 2020. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 87(4):281–286. doi:10.1007/s12098-020-03263-6.
   PubMed Web of Science ®Google Scholar
• Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. 2009. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother. 64(4):741–746. doi:10.1093/jac/dkp274.
   PubMed Web of Science ®Google Scholar
• Sunkara N, Vijayalakshmi A. 2017. UV spectrophotometric method development and validation of lopinavir in bulk and in pharmaceutical dosage form. CIBTech J Pharma Sci. 6(2):1–4.
   Web of Science ®Google Scholar
• Thakkar H, Patel K. 2010. A first-derivative spectrophotometric method for the estimation of Lopinavir in tablets. p. Chron Young Scient. 1(3):22–22.
   Google Scholar
• Tuesuwan B, Mueannoom W, Jamnongtanachot P, Khunvichai A, Pavitrapok C, Wongpakdee K, Sra-Ium S, Mahanonda N, Vongsutilers V. 2023. Basis to aid crisis: favipiravir oral solution for hospital compounding during COVID-19 drug shortage. J Pharm Sci. 112(2):610–617. doi:10.1016/j.xphs.2022.10.026.
   PubMed Web of Science ®Google Scholar
• Vargas DF, Larghi EL, Kaufman TS. 2021. Evolution of the synthesis of Remdesivir. classical approaches and most recent advances. ACS Omega. 6(30):19356–19363. doi:10.1021/acsomega.1c03082.
   PubMed Web of Science ®Google Scholar
• Velozo CT, Cabral LM, Pinto EC, de Sousa VP. 2022. Lopinavir/Ritonavir: a review of analytical methodologies for the drug substances, pharmaceutical formulations and biological matrices. Crit Rev Anal Chem. 52(8):1846–1862. doi:10.1080/10408347.2021.1920364.
   PubMed Web of Science ®Google Scholar
• Vemuri DK, Gundla R, Konduru N, Mallavarapu R, Katari NK. 2022. Favipiravir (SARS‐CoV‐2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC–MS method. Biomed Chromatogr. 36(6):e5363. doi:10.1002/bmc.5363.
   PubMed Web of Science ®Google Scholar
• Xiao D, John Ling KH, Tarnowski T, Humeniuk R, German P, Mathias A, Chu J, Chen Y-S, van Ingen E. 2021. Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. Anal Biochem. 617:114118. doi:10.1016/j.ab.2021.114118.
   PubMed Web of Science ®Google Scholar
• Yadav AK, et al. 2023. A review on drug stability. International Journal of Science and Research Archive. 9(1):474–485.
   Google Scholar
• Yang K. 2020. What do we know about remdesivir drug interactions? Clin Transl Sci. 13(5):842–844. doi:10.1111/cts.12815.
   PubMed Web of Science ®Google Scholar
• Yao Y, et al. 2010. LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma. Yao Xue Xue Bao = Acta Pharmaceutica Sinica. 45(2):279–282.
   PubMedGoogle Scholar